COVID-19 and Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers: What Is the Evidence?

JAMA - Journal of the American Medical Association

Volumn 323, Issue 18, 2020, Pages 1769-1770

  Patel, Ankit B ^a   Verma, Ashish ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN CONVERTING ENZYME 2; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR ANTAGONIST; ANGIOTENSIN[1-7]; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ANTIHYPERTENSIVE AGENT; DIPEPTIDYL CARBOXYPEPTIDASE;

ADULT RESPIRATORY DISTRESS SYNDROME; COMORBIDITY; CORONAVIRUS DISEASE 2019; DIABETES MELLITUS; DISEASE EXACERBATION; ENZYME INHIBITION; EVIDENCE BASED MEDICINE; HEART DISEASE; HOSPITAL MORTALITY; HOST CELL; HUMAN; HYPERTENSION; KIDNEY DISEASE; LUNG DISEASE; LUNG INJURY; MORBIDITY; MORTALITY RATE; NONHUMAN; NOTE; PANDEMIC; PATHOGENESIS; PRIORITY JOURNAL; SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2; VIRUS CELL INTERACTION; VIRUS ENTRY; ANIMAL; BETACORONAVIRUS; COMPLICATION; CORONAVIRUS INFECTION; DRUG EFFECT; ENZYMOLOGY; METABOLISM; MOUSE; PATHOGENICITY; PHYSIOLOGY; SARS CORONAVIRUS; VASODILATATION; VIRUS PNEUMONIA;

ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; ANTIHYPERTENSIVE AGENTS; BETACORONAVIRUS; CORONAVIRUS INFECTIONS; HUMANS; HYPERTENSION; LUNG INJURY; MICE; PANDEMICS; PEPTIDYL-DIPEPTIDASE A; PNEUMONIA, VIRAL; SARS VIRUS; VASODILATION; VIRUS INTERNALIZATION;

EID: 85082520475     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2020.4812     Document Type: Note

References (9)

1. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention. JAMA. Published online February 24, 2020. doi: 10.1001/jama.2020.2648 32091533
2. Wu C, Chen X, Cai Y, Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med. Published online March 13, 2020. doi: 10.1001/jamainternmed.2020.0994 32167524
3. Zhou F, Yu T, Du R, Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;
4. Zhou P, Yang X-L, Wang X-G, A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020; 579 (7798): 270-273. doi: 10.1038/s41586-020-2012-7 32015507
5. Rice GI, Thomas DA, Grant PJ, Turner AJ, Hooper NM. Evaluation of angiotensin-converting enzyme (ACE), its homologue ACE2 and neprilysin in angiotensin peptide metabolism. Biochem J. 2004; 383 (pt 1): 45-51. doi: 10.1042/BJ20040634 15283675
6. Kuba K, Imai Y, Rao S, A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. Nat Med. 2005; 11 (8): 875-879. doi: 10.1038/nm1267 16007097
7. Khan A, Benthin C, Zeno B, A pilot clinical trial of recombinant human angiotensin-converting enzyme 2 in acute respiratory distress syndrome. Crit Care. 2017; 21 (1): 234. 28877748
8. European Society of Cardiology. Position statement of the ESC Council on Hypertension on ACE-inhibitors and angiotensin receptor blockers. Published March 13, 2020. Accessed March 20, 2020. http://www.escardio.org/Councils/Council-on-Hypertension-(CHT)/News/position-statement-of-the-esc-council-on-hypertension-on-ace-inhibitors-and-ang
9. American Heart Association. HFSA/ACC/AHA statement addresses concerns re: using RAAS antagonists in COVID-19. Accessed March 20, 2020. http://professional.heart.org/professional/ScienceNews/UCM-505836-HFSAACCAHA-statement-addresses-concerns-re-using-RAAS-antagonists-in-COVID-19.jsp